PPA24

PPA24 is a PP2A activator with a KD of 8.465 μM for PP2ACα. PPA24 induces cancer cell death via apoptosis. PP2ACα induces ROS generation and decreases the level of c-Myc expression. PPA24 can be used to study colorectal cancer (CRC), Folinic acid (HY-17556), 5-Fluorouracil (HY-90006), and Oxaliplatin (HY-17371) (FOLFOX) -resistant CRC, and melanoma cancer[1][2][3].

Product Specifications

CAS Number

[3035032-77-7]

UNSPSC

12352005

Target

Apoptosis; c-Myc; ERK; GSK-3; Phosphatase; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ppa24.html

Purity

98.09

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC1=CC=C2C(N(C3=CC=CC=C3S2)CCCC[N+]4(C[N@@](C5)C6)C[N@@]6C[N@@]5C4)=C1.[Br-]

Molecular Formula

C22H27BrClN5S

Molecular Weight

508.91

References & Citations

[1]Johnson H, et al. Identification of a Novel Protein Phosphatase 2A Activator, PPA24, as a Potential Therapeutic for FOLFOX-Resistant Colorectal Cancer. J Med Chem. 2024 Oct 24;67 (20) :18070-18089.|[2]Hannah Johnson, et al.Sharma; Abstract 1655: Discovery of a novel PP2A activator as a potential therapeutic for FOLFOX resistant colon cancer. Cancer Res 1 April 2023; 83 (7_Supplement) : 1655.|[3]Hannah Johnson, et al. Abstract 7273: Small molecule activation of PP2A in the treatment of melanoma. Cancer Res 15 March 2024; 84 (6_Supplement) : 7273.